Takafumi Nakano1,2, Ryuji Yasumatsu3, Kazuki Hashimoto1, Ryosuke Kuga1, Takahiro Hongo1, Hidetaka Yamamoto4, Mioko Matsuo1, Takahiro Wakasaki1, Rina Jiromaru1, Tomomi Manako1, Satoshi Toh2, Muneyuki Masuda2, Moriyasu Yamauchi5, Yuichiro Kuratomi5, Hideoki Uryu6, Torahiko Nakashima6, Akihiro Tamae7, Risa Tanaka8, Masahiko Taura9, Toranoshin Takeuchi10, Takamasa Yoshida11, Takashi Nakagawa1. 1. Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 2. Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan. 3. Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; yasumatsu.ryuji.847@m.kyushu-u.ac.jp. 4. Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 5. Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of Medicine, Saga, Japan. 6. Division of Otorhinolaryngology and Head and Neck Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan. 7. Department of Otolaryngology, Hamanomachi Hospital, Fukuoka, Japan. 8. Department of Internal Medicine, Hamanomachi Hospital, Fukuoka, Japan. 9. Department of Otolaryngology Fukuoka University School of Medicine, Fukuoka, Japan. 10. Department of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan. 11. Department of Otolaryngology, Sasebo Kyosai Hospital, Sasebo, Japan.
Abstract
BACKGROUND/AIM: Surgery remains the standard treatment for salivary gland carcinoma (SGC). Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment with cisplatin/carboplatin and 5-fluorouracil plus cetuximab (EXTREME). PATIENTS AND METHODS: We retrospectively collected 19 SGCs from patients treated with the EXTREME regimen. After analyzing EGFR expression and gene copy number gain, we evaluated the correlation between EGFR status and clinicopathological factors and prognosis. RESULTS: EGFR overexpression was detected in 77.8% cases, but not statistically associated with clinicopathological factors or prognosis. EGFR gene copy number gain was detected in 16.7% cases, and statistically positively correlated with lymph node metastasis (p=0.0291). The best overall response was partial response in two cases, stable disease in 15, and progressive disease in one case. The EXTREME regimen was discontinued in all cases. CONCLUSION: Our results suggest that SGCs are positive for EGFR protein expression but the response rate to the EXTREME regimen was unremarkable.
BACKGROUND/AIM: Surgery remains the standard treatment for salivary gland carcinoma (SGC). Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment with cisplatin/carboplatin and 5-fluorouracil plus cetuximab (EXTREME). PATIENTS AND METHODS: We retrospectively collected 19 SGCs from patients treated with the EXTREME regimen. After analyzing EGFR expression and gene copy number gain, we evaluated the correlation between EGFR status and clinicopathological factors and prognosis. RESULTS: EGFR overexpression was detected in 77.8% cases, but not statistically associated with clinicopathological factors or prognosis. EGFR gene copy number gain was detected in 16.7% cases, and statistically positively correlated with lymph node metastasis (p=0.0291). The best overall response was partial response in two cases, stable disease in 15, and progressive disease in one case. The EXTREME regimen was discontinued in all cases. CONCLUSION: Our results suggest that SGCs are positive for EGFR protein expression but the response rate to the EXTREME regimen was unremarkable.
Authors: T Nakano; R Yasumatsu; R Kogo; K Hashimoto; K Asai; S Ohga; H Yamamoto; T Nakashima; T Nakagawa Journal: J Laryngol Otol Date: 2019-06-06 Impact factor: 1.469
Authors: Elham Jouzdani; Jacques Yachouh; Valérie Costes; Jean Luc Faillie; César Cartier; Flora Poizat; Guillemette Pierre; Vincent Burcia; Marc Makeieff; Louis Crampette; Bernard Guerrier; Renaud Garrel Journal: Eur J Cancer Date: 2010-01 Impact factor: 9.162
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Laura D Locati; Federica Perrone; Marco Losa; Micol Mela; Paola Casieri; Marta Orsenigo; Barbara Cortelazzi; Tiziana Negri; Elena Tamborini; Pasquale Quattrone; Paolo Bossi; Gaetana Rinaldi; Cristiana Bergamini; Rosa G Calderone; Cecilia Liberatoscioli; Lisa Licitra Journal: Oral Oncol Date: 2009-07-01 Impact factor: 5.337
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245
Authors: David M Cognetti; Jennifer M Johnson; Joseph M Curry; Samith T Kochuparambil; Darren McDonald; Frank Mott; Mary J Fidler; Kerstin Stenson; Nilesh R Vasan; Mohammad A Razaq; John Campana; Patrick Ha; Grace Mann; Kosuke Ishida; Miguel Garcia-Guzman; Merrill Biel; Ann M Gillenwater Journal: Head Neck Date: 2021-10-09 Impact factor: 3.821